Table 2 Baseline patient characteristics in the NEURO-TTR trial, full analysis set (N = 165)
|  | Inotersen (n = 106) | Placebo (n = 59) |
|---|---|---|
Age, mean (SD) | 59.6 (12.4) | 59.4 (14.1) |
Sex, N (%) | ||
 Male | 75 (71) | 41 (70) |
 Female | 31 (29) | 18 (30) |
Mutation Type, N (%) | ||
 V30M | 54 (51) | 33 (56) |
 Non-V30M | 52 (49) | 26 (44) |
FAP stage, N (%) | ||
 Stage 1 (ambulatory without assistance) | 71 (67) | 42 (71) |
 Stage 2 (ambulatory with assistance) | 35 (33) | 17 (29) |
Previous treatment statusa, N (%) | ||
 Pretreatment | 62 (59) | 35 (59) |
 No pretreatment | 44 (41) | 24 (41) |
Cardiomyopathy status, N (%) | ||
 Cardiomyopathy | 70 (66) | 32 (54) |
 No cardiomyopathy | 36 (34) | 27 (46) |
Age of symptom onset, N (%) | ||
 Early onset | 31 (29) | 20 (34) |
 Late onset | 75 (71) | 39 (66) |
NIS, mean (SD) | ||
 Total | 46.6 (25.7) | 43.4 (24.7) |
 Muscle Weakness | 21.2 (17.5) | 20.0 (16.1) |
 Sensation | 14.4 (6.3) | 13.3 (6.9) |
 Reflexes | 10.9 (6.0) | 10.1 (6.4) |
NIS-LL, mean (SD) | ||
 Total | 30.1 (15.5) | 28.7 (16.0) |
 Muscle Weakness | 13.9 (11.3) | 13.4 (11.0) |
 Sensation | 10.2 (4.0) | 9.8 (4.5) |
 Reflexes | 6.0 (2.3) | 5.6 (2.7) |